cue-101
Recombinant proteinexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2019 (NCT03978689)
Timeline
Indications
Mechanism of action
- Human papillomavirusINHIBITOR
Human papillomavirus inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07172256 | Phase 2 | Nov 30, 2025 | Cue Biopharma, National Cancer Institute (NCI), Yale University |
| NCT04852328 | Phase 2 | Nov 30, 2021 | Cue Biopharma, Washington University in St. Louis |
| NCT03978689 | Phase 1 | Jun 30, 2019 | Cue Biopharma |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cue Biopharma | For profit | 3 | 1 | 2 | 2019 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2025 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Yale University | Academic/Hospital | 1 | 1 | 1 | 2025 |
4 organizations
Page 1 / 1